Physicians' Academy for Cardiovascular Education

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

VBWG at ACC 2018 After lack of sham-controlled trials, the SPYRAL program has started to test the efficacy of renal denervation in patients with uncontrolled hypertension. Two pilot studies with a sham controlled group in patients without and with medications are nearly finished.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the VBWG at ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.

Faculty

Michael Böhm, MD, FESC is professor of internal medicine and cardiology and director of Internal Medicine at Saarland University, Homburg, Saarland, Germany.

Disclosures

This 3-minute education provides a summary of just presented scientific data, recorded during the VBWG at ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: